IKT
Inhibikase Therapeutics Inc

1,881
Mkt Cap
$202.52M
Volume
311,473.00
52W High
$3.32
52W Low
$1.33
PE Ratio
-2.93
IKT Fundamentals
Price
$1.65
Prev Close
$1.67
Open
$1.65
50D MA
$1.64
Beta
0.96
Avg. Volume
604,455.77
EPS (Annual)
-$1.16
P/B
1.71
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Inhibikase Therapeutics (NYSE:IKT) Trading Up 1.2% - What's Next?
Inhibikase Therapeutics (NYSE:IKT) Shares Up 1.2% - What's Next...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Short Interest in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Rises By 29.0%
Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling...
MarketBeat·21d ago
News Placeholder
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Brokerages
Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has earned a consensus recommendation of "Buy" from the five analysts that are presently covering the company, MarketBeat reports. One...
MarketBeat·24d ago
News Placeholder
Inhibikase Therapeutics (NASDAQ:IKT) Raised to "Strong-Buy" at HC Wainwright
HC Wainwright raised shares of Inhibikase Therapeutics to a "strong-buy" rating in a research report on Friday...
MarketBeat·24d ago
News Placeholder
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Sell at Wall Street Zen
Wall Street Zen raised Inhibikase Therapeutics to a "sell" rating in a report on Saturday...
MarketBeat·25d ago
News Placeholder
Inhibikase Therapeutics (NYSE:IKT) Receives Buy Rating from HC Wainwright
HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of Inhibikase Therapeutics in a research note on Friday...
MarketBeat·25d ago
News Placeholder
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Strong-Buy at Cantor Fitzgerald
Cantor Fitzgerald raised shares of Inhibikase Therapeutics to a "strong-buy" rating in a research note on Thursday...
MarketBeat·1mo ago
News Placeholder
Cantor Fitzgerald Initiates Coverage on Inhibikase Therapeutics (NYSE:IKT)
Cantor Fitzgerald initiated coverage on Inhibikase Therapeutics in a report on Thursday. They issued an "overweight" rating and a $4.00 price target on the stock...
MarketBeat·1mo ago
News Placeholder
FY2025 Earnings Estimate for IKT Issued By Lifesci Capital
Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) - Lifesci Capital issued their FY2025 EPS estimates for Inhibikase Therapeutics in a report issued on Monday, December 1st. Lifesci Capital...
MarketBeat·2mo ago
News Placeholder
Inhibikase Therapeutics (NASDAQ:IKT) Issues Quarterly Earnings Results
Inhibikase Therapeutics (NASDAQ:IKT - Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.13) earnings per share for the quarter...
MarketBeat·2mo ago
<
1
2
...
>

Latest IKT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.